Oral afatinib ( Gilotrif ) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer ( NSCLC ) who have tumours with EGFR exon 19 deletions or exon 21 ( L858R ) substitution mutations as detected by a US FDA-approved test .